Baseline clinical and angiographic data in the quinapril ischemic event (QUIET) Trial

The QUinapril Ischemic Event Trial (QUIET) is the first prospective, double-blind, placebo-controlled trial to investigate the long-term antiatherosclerotic effects of angiotensin-converting enzyme inhibition. Normotensive, nonhyperlipidemic subjects (1,750) with normal left ventricular systolic function were randomly assigned to treatment or placebo at percutaneous transluminal coronary angioplasty (PTCA). The primary end point is time to first cardiac ischemic event. Baseline clinical characteristics are (mean ± SD): age 58 ± 9 years; blood pressure 123 ± 1574 ± 10mm Hg; low density lipoprotein cholesterol 124 ± 27 mg/dL; high density lipoprotein cholesterol 37 ± 10 mg/dL; and triglycerides 167 ± 91 mg/dL. In addition, 81% are men; 22% are current smokers; 49% give a history of myocardial infarction. Baseline angiographic characteristics are (mean ± SD): left ventricular ejection fraction 59% ± 11%; per patient diameter stenosis (excluding the PTCA segment) 49% ±31%; 8.9 ± 3.5 analyzable segments per patient (excluding the PTCA segment), 3.8 ± 2.3 of which have visible stenosis. Including the PTCA segment, 52% have single vessel disease and 48% have multivessel disease. Baseline angiographic data for non-PTCA segments will be correlated with cardiac ischemic events which occur after 6 months. Up to 500 subjects will undergo followup angiography with quantitative coronary angiographic analysis (QCA) of baseline and follow-up films. The primary QCA end point will be per-patient categorical designation as progresser or nonprogressor based on the presence or absence of ≥400 μm narrowing in ≥ 1 vessels that did not undergo PTCA.